Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013 [EXTENSION OF 700009915]

Next Previous
X
Search
Trial Profile

A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013 [EXTENSION OF 700009915]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04A
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms HPV-025 EXT 013
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 11 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00877877).
    • 21 Feb 2013 Planned number of patients changed to 600.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top